Axogen, INC Form 4 insider transactions

Axogen, Inc. Director Joseph A. Tyndall reported exercising stock options and subsequently selling a significant portion of the acquired shares, totaling 20,062 shares, under a Rule 10b5-1 plan.

Axogen, Inc. Director Joseph A. Tyndall reported the sale of 2,525 shares of common stock at a price of $11.63 per share, reducing his direct beneficial ownership to 22,557 shares.

Axogen's CFO, Lindsey Marie Hartley, reported the acquisition of 26,000 restricted stock units in a recent SEC Form 4 filing.

Chief Marketing Officer Jens Kemp reports the acquisition of 38,000 restricted stock units in Axogen, Inc.

Erick Wayne DeVinney, Chief Innovation Officer of Axogen, Inc., reports the acquisition of 38,000 restricted stock units (RSUs) on March 25, 2025, vesting over a four-year period.

Axogen's CEO, Michael Dale, reported the acquisition of 176,300 restricted stock units, which will vest over a four-year period.

Axogen's EVP & General Counsel, Marc Began, reports the acquisition of 55,000 restricted stock units (RSUs) in a recent SEC filing.

Erick DeVinney, Chief Innovation Officer of Axogen, Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Jens Kemp, Chief Marketing Officer of Axogen, Inc., reports the acquisition and disposal of company shares, along with a correction to a previously filed Form 4 regarding restricted stock units.

Jens Kemp, Axogen's Chief Marketing Officer, sold 4,003 shares of common stock on March 4, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Marc Began, EVP & General Counsel of Axogen, Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Director Amy McBride Wendell sold 5,000 shares of Axogen, Inc. common stock on March 3, 2025, at a weighted average price of $20.02 per share, according to a Form 4 filing with the SEC.

Erick Wayne DeVinney, Axogen's Chief Innovation Officer, reports the acquisition and disposal of company stock related to performance stock units and tax obligations.

Jens Kemp, Chief Marketing Officer of Axogen, Inc., reports the acquisition and disposal of company stock related to performance stock units and tax obligations.

Marc Began, EVP & General Counsel of Axogen, Inc., reports the acquisition and disposition of company stock related to performance stock units and tax obligations.

Chief Innovation Officer Erick Wayne DeVinney reports acquisition and disposal of Axogen, Inc. shares related to performance stock unit vesting and tax obligations.

Axogen's CFO, Nir Naor, sold 39,132 shares of common stock to cover tax obligations related to vesting restricted stock units.

Director Paul Thomas reports acquiring 2,875 shares of Axogen, Inc. common stock related to his appointment as Chairman of the Board.

Erick Wayne DeVinney, Chief Innovation Officer of Axogen, Inc., reports acquiring 2,500 shares of common stock on September 13, 2024, resulting in a total beneficial ownership of 179,974 shares.

Director John Johnson reports the vesting of 11,904 restricted stock units of Axogen, Inc. on September 1, 2024.

Director Guido J. Neels reports the vesting of 11,904 restricted stock units into common stock on September 1, 2024.

Alan M. Levine, a director of Axogen, Inc., reported the vesting of 11,904 restricted stock units on September 1, 2024, resulting in ownership of 40,816 common stock shares.

Director William P. Burke reported the vesting of 11,904 restricted stock units of Axogen, Inc. on September 1, 2024.

Director Paul Thomas reports the vesting of 11,904 restricted stock units of Axogen, Inc. on September 1, 2024.

Director Joseph A. Tyndall reports the vesting of 11,904 restricted stock units into common stock on September 1, 2024.

Director Amy McBride Wendell reports the vesting of 11,904 restricted stock units into common stock on September 1, 2024.

Axogen's CEO, Michael Dale, was granted 450,000 performance stock units (PSUs) as an inducement to his employment.

Amy McBride Wendell, a director at Axogen, Inc., reported the acquisition of common stock and stock options as part of her annual equity grant.

Director William P. Burke reports acquisition of Axogen shares and stock options as part of an annual equity grant.

Director John Johnson reports acquiring shares and stock options in Axogen, Inc. as part of an annual equity grant.